Lu-Yao G, Nikita N, Keith SW, et al. - This study attempted to evaluate the short-term results of abiraterone acetate (AA) and enzalutamide (ENZ) in patients with pre-existing cardiovascular disease (CVD). A population-based retrospective study was conducted to utilize Surveillance, Epidemiology, and End Results-Medicare–linked database to distinguish prostate cancer individuals using AA or ENZ. The primary outcomes included 6-mo all-cause mortality, examined using modified Poisson regression modeling of relative risk (RR) adjusted for confounders and comorbidities. This study found that 67% had at least one pre-existing CVD among eligible individuals (2,845 with AA and 1,031 with ENZ). It was noted that elderly prostate cancer individuals with pre-existing CVDs experienced higher short-term mortality than otherwise similar patients without CVDs after treatment with AA or ENZ. The results indicated that mortality correlated with CVDs did not depend on having received AA vs ENZ.